351 related articles for article (PubMed ID: 34603319)
21. Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines.
Chen Y; Zhang C; Li Y; Tan X; Li W; Tan S; Liu G
Sci Rep; 2024 Feb; 14(1):3219. PubMed ID: 38331967
[TBL] [Abstract][Full Text] [Related]
22. Identification of Potential Antigens for Developing mRNA Vaccine for Immunologically Cold Mesothelioma.
Zhang S; Li S; Wei Y; Xiong Y; Liu Q; Hu Z; Zeng Z; Tang F; Ouyang Y
Front Cell Dev Biol; 2022; 10():879278. PubMed ID: 35846349
[TBL] [Abstract][Full Text] [Related]
23. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
[TBL] [Abstract][Full Text] [Related]
24. Identification of Tumor Antigens and Immune Landscape in Glioblastoma for mRNA Vaccine Development.
Ye L; Wang L; Yang J; Hu P; Zhang C; Tong S; Liu Z; Tian D
Front Genet; 2021; 12():701065. PubMed ID: 34527020
[No Abstract] [Full Text] [Related]
25. Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis.
Zhao B; Wang Y; Wang Y; Dai C; Wang Y; Ma W
Front Immunol; 2021; 12():557994. PubMed ID: 34220791
[TBL] [Abstract][Full Text] [Related]
26. Hypoxia-Related lncRNA Correlates With Prognosis and Immune Microenvironment in Lower-Grade Glioma.
Xu S; Tang L; Liu Z; Luo C; Cheng Q
Front Immunol; 2021; 12():731048. PubMed ID: 34659218
[TBL] [Abstract][Full Text] [Related]
27. Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine.
Tan H; Yu T; Liu C; Wang Y; Jing F; Ding Z; Liu J; Shi H
Cancer Med; 2022 Dec; 11(23):4656-4672. PubMed ID: 35593226
[TBL] [Abstract][Full Text] [Related]
28. An Immune-Related Signature for Predicting the Prognosis of Lower-Grade Gliomas.
Zhang H; Li X; Li Y; Chen B; Zong Z; Shen L
Front Immunol; 2020; 11():603341. PubMed ID: 33363544
[TBL] [Abstract][Full Text] [Related]
29. Classification of diffuse lower-grade glioma based on immunological profiling.
Wu F; Wang ZL; Wang KY; Li GZ; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Zhao Z; Zhang W
Mol Oncol; 2020 Sep; 14(9):2081-2095. PubMed ID: 32392361
[TBL] [Abstract][Full Text] [Related]
30. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
[TBL] [Abstract][Full Text] [Related]
31. Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development.
Wang ZL; Huang RY; Han B; Wu F; Sun ZY; Li GZ; Zhang W; Zhao Z; Liu X
Chin Neurosurg J; 2022 Oct; 8(1):34. PubMed ID: 36307882
[TBL] [Abstract][Full Text] [Related]
32. Isocitrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas.
Kohanbash G; Carrera DA; Shrivastav S; Ahn BJ; Jahan N; Mazor T; Chheda ZS; Downey KM; Watchmaker PB; Beppler C; Warta R; Amankulor NA; Herold-Mende C; Costello JF; Okada H
J Clin Invest; 2017 Apr; 127(4):1425-1437. PubMed ID: 28319047
[TBL] [Abstract][Full Text] [Related]
33. A vaccine targeting mutant IDH1 induces antitumour immunity.
Schumacher T; Bunse L; Pusch S; Sahm F; Wiestler B; Quandt J; Menn O; Osswald M; Oezen I; Ott M; Keil M; Balß J; Rauschenbach K; Grabowska AK; Vogler I; Diekmann J; Trautwein N; Eichmüller SB; Okun J; Stevanović S; Riemer AB; Sahin U; Friese MA; Beckhove P; von Deimling A; Wick W; Platten M
Nature; 2014 Aug; 512(7514):324-7. PubMed ID: 25043048
[TBL] [Abstract][Full Text] [Related]
34. The CXCL Family Contributes to Immunosuppressive Microenvironment in Gliomas and Assists in Gliomas Chemotherapy.
Wang Z; Liu Y; Mo Y; Zhang H; Dai Z; Zhang X; Ye W; Cao H; Liu Z; Cheng Q
Front Immunol; 2021; 12():731751. PubMed ID: 34603309
[TBL] [Abstract][Full Text] [Related]
35. Three Immune-Associated Subtypes of Diffuse Glioma Differ in Immune Infiltration, Immune Checkpoint Molecules, and Prognosis.
Zhou Q; Yan X; Liu W; Yin W; Xu H; Cheng D; Jiang X; Ren C
Front Oncol; 2020; 10():586019. PubMed ID: 33425739
[TBL] [Abstract][Full Text] [Related]
36. Preparation of hepatocellular carcinoma mRNA vaccines based on potential tumor targets and immunophenotypes.
Wang HK; Xu XH; Wang SM; Zhang HY
Transl Cancer Res; 2024 Jan; 13(1):173-190. PubMed ID: 38410201
[TBL] [Abstract][Full Text] [Related]
37. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
[TBL] [Abstract][Full Text] [Related]
38. In silico identification of the prognostic biomarkers and therapeutic targets associated with cancer stem cell characteristics of glioma.
Lvu W; Fei X; Chen C; Zhang B
Biosci Rep; 2020 Aug; 40(8):. PubMed ID: 32725165
[TBL] [Abstract][Full Text] [Related]
39. Comprehensive analysis of m
Zhao K; Li W; Yang Y; Hu X; Dai Y; Huang M; Luo J; Zhang K; Zhao N
Front Immunol; 2022; 13():955848. PubMed ID: 36203569
[TBL] [Abstract][Full Text] [Related]
40. Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer.
Zhang X; Zhang Y; Zhao L; Wang J; Li J; Wang X; Zhang M; Hu X
Front Immunol; 2022; 13():1014638. PubMed ID: 36569935
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]